GO:0005684 U2-type spliceosomal complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005684 defines the U2-type spliceosomal complex, the macromolecular machine that removes canonical GT-AG introns from messenger RNA primary transcripts.
• The U2-type spliceosome is the major spliceosome in eukaryotes, contrasting with the minor U12-type spliceosome that processes a rare class of introns.
• Evolutionary evidence suggests that primordial spliceosomal introns were predominantly U2-type, making this complex central to eukaryotic gene architecture.
• Core components include U1, U2, U4/U6, and U5 snRNPs plus numerous auxiliary proteins such as SF3B4, which is implicated in both splicing and cancer.
• Dysregulation of U2-type spliceosomal components, such as USP15-mediated regulation, is linked to non-small cell lung cancer progression and chemoresistance.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable functional dissection of U2-type spliceosomal genes in disease contexts.
Description
The U2-type spliceosomal complex (GO:0005684) is a cellular component defined as any spliceosomal complex that forms during the splicing of a messenger RNA primary transcript to excise an intron that has canonical consensus sequences near the 5' and 3' ends. This complex is responsible for the removal of the vast majority of introns in eukaryotic cells, which typically begin with GT and end with AG dinucleotides. It is also known as the major spliceosomal complex or GT-AG spliceosome, distinguishing it from the minor U12-type spliceosome that processes a rare class of introns with distinct consensus sequences. Researchers study GO:0005684 because it is fundamental to gene expression, and its dysfunction is increasingly linked to human diseases, including cancer. The U2-type spliceosome is not a static entity but a dynamic assembly of small nuclear ribonucleoproteins (snRNPs) and associated proteins that undergo ordered rearrangements to catalyze intron excision. Understanding its composition, assembly, and regulation provides insights into basic RNA biology and offers therapeutic targets for splicing-related disorders. This article integrates authoritative QuickGO data with real PubMed literature to provide a research-grade overview of the U2-type spliceosomal complex, covering its definition, structure, molecular mechanism, key genes, disease relevance, and experimental models for functional studies.
U2-type spliceosomal complex At A Glance
| GO ID | GO:0005684 |
|---|---|
| GO term | U2-type spliceosomal complex |
| Ontology | cellular_component |
| Synonym | GT-AG spliceosome; major spliceosomal complex; major (U2-type) spliceosomal complex |
| Major function | Excises canonical GT-AG introns from pre-mRNA during splicing |
| Composition | U1, U2, U4/U6, and U5 snRNPs plus auxiliary proteins such as SF3B4 |
| Evolutionary origin | Primordial spliceosomal introns were probably U2-type |
| Disease relevance | Dysregulation linked to cancer progression and chemoresistance |
What Is GO:0005684?
The U2-type spliceosomal complex is a large ribonucleoprotein assembly that forms on precursor messenger RNA (pre-mRNA) to remove introns bounded by canonical GT-AG consensus sequences at the 5' and 3' splice sites. It is the major spliceosome in eukaryotes, as opposed to the minor U12-type spliceosome, which processes a rare class of introns with AT-AC termini. The complex comprises multiple small nuclear RNAs (snRNAs) and hundreds of proteins that coordinate the two transesterification reactions of splicing.
Why Is U2-type spliceosomal complex Important in Cell Biology?
The U2-type spliceosomal complex is essential for the expression of most eukaryotic genes, as it catalyzes the removal of canonical introns from pre-mRNA. Its correct function ensures proteome diversity through alternative splicing, and its dysregulation is associated with a growing list of human diseases, including non-small cell lung cancer and other malignancies. Moreover, evolutionary studies indicate that U2-type introns were likely the primordial form, underscoring their central role in eukaryotic evolution. Thus, understanding this complex is critical for both basic biology and translational research.
• Processes the majority of human introns, which are U2-type with GT-AG boundaries.
• Enables alternative splicing, expanding proteome diversity from a limited number of genes.
• Dysregulation of U2-type spliceosomal components is implicated in cancer progression and chemoresistance.
• Mutations in spliceosomal genes can cause splicing-related diseases, including cancer and potentially neurodegeneration.
• Evolutionary conservation highlights its ancient origin and fundamental role in eukaryotes.
• Serves as a target for therapeutic intervention in splicing-driven cancers.
• Provides a model system for studying RNA-protein interactions and dynamic RNP assembly.
• CRISPR-based editing of spliceosomal genes allows functional dissection of their roles in disease.
• Bioinformatics analysis of U2-type spliceosomal gene expression can reveal prognostic signatures.
• Understanding U2-type splicing is essential for interpreting the impact of minor intron splicing dysregulation.
What Happens During U2-type spliceosomal complex?
Early Recognition of Splice Sites
In simple terms: The spliceosome first identifies the beginning and end of the intron to be removed.
The U2-type spliceosomal complex assembles on pre-mRNA through the recognition of canonical GT-AG splice sites. The U1 snRNP binds the 5' splice site, while SF1 and U2AF recognize the branch point and 3' splice site, respectively. This early recognition is crucial for defining the intron and initiating assembly.
Assembly of the Spliceosomal Complex
In simple terms: Multiple RNA-protein machines come together to form the active spliceosome.
The U2 snRNP is recruited to the branch point, displacing SF1, and then the U4/U6.U5 tri-snRNP joins to form the mature spliceosome. This dynamic assembly involves numerous protein factors, including SF3B4, which is a component of the U2 snRNP and plays a versatile role in eukaryotic cells. The complex undergoes extensive rearrangements to become catalytically active.
Catalysis of Splicing
In simple terms: The spliceosome cuts the intron at both ends and joins the exons together.
The activated spliceosome catalyzes two transesterification reactions: first, the branch point adenosine attacks the 5' splice site, forming a lariat intermediate; second, the 3' splice site is attacked, ligating the exons and releasing the intron lariat. This process is highly conserved and requires the U2-type spliceosomal complex.
Disassembly and Recycling
In simple terms: After splicing, the spliceosome falls apart and its components are reused.
Following catalysis, the spliceosome disassembles in an ATP-dependent manner, releasing the spliced mRNA and intron lariat, and the snRNPs are recycled for subsequent rounds of splicing. This step is essential for maintaining splicing efficiency and cellular homeostasis.
Key Genes Involved in GO:0005684 U2-type spliceosomal complex
The U2-type spliceosomal complex comprises numerous genes encoding snRNAs and proteins; key examples include core snRNP components and auxiliary factors with established roles in splicing and disease.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SF3B4 | Component of U2 snRNP; involved in branch point recognition | Implicated in cancer and developmental disorders; versatile player in eukaryotic cells |
| U2AF1 | Recognizes 3' splice site and recruits U2 snRNP | Frequently mutated in myeloid malignancies and lung cancer |
| U2AF2 | Binds polypyrimidine tract and assists U2AF1 | Essential for splice site selection; potential therapeutic target |
| SF3B1 | Core component of U2 snRNP; hotspot mutations in cancer | Mutations linked to myelodysplasia and other cancers |
| SF3A1 | Part of SF3a complex required for U2 snRNP maturation | Involved in spliceosome assembly and cancer |
| PRPF8 | Component of U5 snRNP; stabilizes catalytic core | Mutations cause retinitis pigmentosa; role in splicing |
| SNRNP200 | U5 snRNP helicase; essential for spliceosome activation | Mutations associated with retinitis pigmentosa |
| DDX46 | RNA helicase involved in spliceosome assembly | Regulates splicing and is implicated in cancer |
| USP15 | Deubiquitinase that regulates U2-type spliceosomal complex | Drives NSCLC progression and chemoresistance |
| RBM39 | Splicing factor associated with U2 snRNP | Target of anticancer drugs; involved in splicing regulation |
| SRSF1 | Serine/arginine-rich splicing factor; modulates splice site selection | Proto-oncogene; dysregulated in many cancers |
| SRSF2 | Splicing factor; binds exonic splicing enhancers | Mutations in myelodysplastic syndromes |
| HNRNPA1 | Heterogeneous nuclear ribonucleoprotein; regulates splicing | Implicated in cancer and neurodegeneration |
| U1-70K | Component of U1 snRNP; recognizes 5' splice site | Autoantigen in autoimmune diseases; role in splicing |
| U2A' | U2 snRNP protein; stabilizes U2 snRNA structure | Essential for U2 snRNP function |
| U5-116kD | U5 snRNP protein; part of catalytic core | Mutations linked to retinitis pigmentosa |
| PRPF6 | U5 snRNP protein; involved in tri-snRNP assembly | Mutations cause retinitis pigmentosa |
How Is U2-type spliceosomal complex Regulated?
The U2-type spliceosomal complex is regulated at multiple levels, including post-translational modifications of its components and interactions with regulatory proteins. For example, the deubiquitinase USP15 has been shown to regulate the U2-type spliceosomal complex, potentially affecting its activity and contributing to non-small cell lung cancer progression and chemoresistance. Additionally, splicing factors such as SF3B4 are subject to autoregulation and can influence splice site selection. Dysregulation of these regulatory mechanisms can lead to aberrant splicing patterns observed in cancer.
U2-type spliceosomal complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| USP15 | Non-small cell lung cancer progression and chemoresistance | Knockout and overexpression in NSCLC cell lines |
| SF3B1 | Myelodysplastic syndromes and other cancers | Point mutation knock-in in hematopoietic cells |
| U2AF1 | Myeloid malignancies and lung cancer | Knockout and point mutation in cancer cell lines |
| SF3B4 | Nager syndrome and cancer | Knockout and overexpression in zebrafish or cell models |
| SRSF2 | Myelodysplastic syndromes | Point mutation knock-in in mouse models |
Cancer Progression and Chemoresistance
Dysregulation of U2-type spliceosomal components is increasingly recognized in cancer. USP15 drives non-small cell lung cancer progression and chemoresistance, potentially via regulation of the U2-type spliceosomal complex. Mutations in splicing factors such as SF3B1 and U2AF1 are common in myeloid malignancies and affect splicing fidelity. These alterations can lead to expression of oncogenic isoforms and contribute to therapy resistance.
Minor Intron Splicing Dysregulation in Cancer
While the U2-type spliceosome processes major introns, dysregulated minor intron splicing (U12-type) has also been implicated in cancer, and cross-talk between the two systems may exist. However, the U2-type complex remains the primary target for therapeutic interventions aimed at splicing in cancer.
Developmental and Neurodegenerative Disorders
Mutations in core spliceosomal genes can cause developmental disorders and neurodegeneration, although direct links to U2-type complex are less characterized. For instance, SF3B4 mutations are associated with Nager syndrome, a developmental disorder. Additionally, splicing dysregulation is a hallmark of several neurodegenerative diseases, though the specific role of U2-type complex requires further study.
From U2-type spliceosomal complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of a U2-type spliceosomal gene affect cell viability? | CRISPR knockout in cancer cell lines |
| Does a specific point mutation in SF3B1 alter splicing patterns? | CRISPR point mutation knock-in in isogenic cell lines |
| Can overexpression of USP15 drive chemoresistance? | CRISPR overexpression in NSCLC cells |
| How does tagging a spliceosomal protein affect its localization? | Knock-in of fluorescent or epitope tags |
| What is the role of SF3B4 in development? | Knockout in model organisms (e.g., zebrafish) |
| Can CRISPR library screening identify synthetic lethal partners? | Genome-wide CRISPR knockout library screening |
How to Study the U2-type spliceosomal complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Splicing patterns and gene expression | Detect splicing changes after knockout or overexpression |
| Proteomics | Protein composition and interactions | Identify spliceosomal components and regulators |
| CRISPR screening | Gene essentiality and synthetic lethality | Discover vulnerabilities in cancer cells |
| Fluorescence microscopy | Subcellular localization and dynamics | Study assembly and localization of spliceosomal proteins |
| RT-PCR | Specific splicing events | Validate splicing changes observed by RNA-seq |
| CLIP-seq | RNA binding sites of splicing factors | Map binding of U2-type spliceosomal proteins on pre-mRNA |
| In vitro splicing assays | Catalytic activity of the spliceosome | Biochemical dissection of splicing mechanisms |
RNA Sequencing (RNA-seq)
RNA-seq is widely used to assess splicing changes upon perturbation of U2-type spliceosomal components. It can detect differential exon usage, intron retention, and alternative splicing events. For example, RNA-seq revealed splicing alterations in NSCLC cells with USP15 modulation.
Proteomics and Immunoprecipitation
Mass spectrometry-based proteomics and immunoprecipitation can identify protein-protein interactions within the U2-type spliceosomal complex and its regulators. These methods help define the composition and dynamic assembly of the spliceosome.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can uncover genes that are essential for splicing or that modulate sensitivity to splicing inhibitors. Such screens have identified U2-type spliceosomal components as vulnerabilities in cancer.
Fluorescence Microscopy
Imaging of fluorescently tagged spliceosomal proteins or snRNAs allows visualization of their subnuclear localization and dynamics in living cells. This approach can reveal assembly defects or mislocalization associated with disease mutations.
How CRISPR Can Be Used to Study GO:0005684 U2-type spliceosomal complex
Knockout
CRISPR knockout of U2-type spliceosomal genes can reveal their essentiality and impact on splicing and cell viability. For example, knockout of USP15 in NSCLC cells reduced tumor progression and chemoresistance, potentially via effects on the U2-type spliceosomal complex. Knockout models are valuable for identifying loss-of-function phenotypes.
Point Mutation
CRISPR point mutation knock-in allows introduction of specific disease-associated mutations, such as those in SF3B1 or U2AF1, to study their effects on splicing and cellular behavior. These models mimic patient mutations and can uncover mechanisms of oncogenesis.
Knock-in
Knock-in of tags (e.g., GFP, HA) or reporter genes into endogenous loci enables visualization and biochemical purification of spliceosomal components. This approach preserves endogenous regulation and can be used to study protein localization and interactions.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can model gain-of-function effects of spliceosomal genes, such as USP15 overexpression driving chemoresistance. Overexpression models help identify oncogenic roles and potential therapeutic targets.
How EDITGENE Supports U2-type spliceosomal complex Research
Researchers studying U2-type spliceosomal complex-related genes often need to determine whether a candidate gene is causally involved in splicing regulation, disease progression, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to enable such functional studies with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for U2-type spliceosomal complex research.
Frequently Asked Questions About U2-type spliceosomal complex
What is the U2-type spliceosomal complex?
The U2-type spliceosomal complex (GO:0005684) is a large ribonucleoprotein assembly that removes canonical GT-AG introns from pre-mRNA during splicing.
What genes are involved in the U2-type spliceosomal complex?
Key genes include SF3B4, U2AF1, SF3B1, PRPF8, and SNRNP200, among many others.
What is the difference between U2-type and U12-type spliceosomes?
U2-type spliceosomes process introns with GT-AG boundaries, while U12-type spliceosomes process a rare class of introns with AT-AC boundaries.
How is the U2-type spliceosomal complex regulated?
It is regulated by post-translational modifications and interacting proteins such as USP15, which can affect its activity in cancer.
What diseases are associated with U2-type spliceosomal complex dysfunction?
Dysregulation is linked to cancer progression, chemoresistance, and developmental disorders.
What methods are used to study the U2-type spliceosomal complex?
Common methods include RNA-seq, proteomics, CRISPR screening, and fluorescence microscopy.
Can CRISPR be used to study U2-type spliceosomal genes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function.
What is the role of SF3B4 in the U2-type spliceosomal complex?
SF3B4 is a component of the U2 snRNP and plays a versatile role in splicing and cancer.
How does USP15 affect the U2-type spliceosomal complex?
USP15 regulates the complex and drives NSCLC progression and chemoresistance, potentially via this regulation.
Why is the U2-type spliceosomal complex important for cancer research?
Because mutations and dysregulation in its components are common in cancers and can be targeted therapeutically.
Conclusion
The U2-type spliceosomal complex (GO:0005684) is a central component of eukaryotic gene expression, responsible for removing the majority of introns from pre-mRNA. Its dynamic assembly and regulation are critical for normal cellular function, and its dysregulation is increasingly linked to human diseases, particularly cancer. Continued research using advanced CRISPR models and multi-omics approaches will further elucidate its roles and therapeutic potential.
References
- 1. Chiu CC et al.. 2025. USP15 Drives NSCLC Progression and Chemoresistance, Potentially via Regulation of the U2-Type Spliceosomal Complex.. Cancer Med 14(15):e71055 PMID: 40762380
- 2. Janice J et al.. 2012. U12-type spliceosomal introns of Insecta.. Int J Biol Sci 8(3):344-52 PMID: 22393306
- 3. Basu MK et al.. 2008. Primordial spliceosomal introns were probably U2-type.. Trends Genet 24(11):525-8 PMID: 18824272
- 4. Nishimura K et al.. 2022. Dysregulated minor intron splicing in cancer.. Cancer Sci 113(9):2934-2942 PMID: 35766428
- 5. Sharp PA et al.. 1997. Classification of introns: U2-type or U12-type.. Cell 91(7):875-9 PMID: 9428511
- 6. Lin CF et al.. 2010. Evolutionary dynamics of U12-type spliceosomal introns.. BMC Evol Biol 10:47 PMID: 20163699
- 7. El Marabti E et al.. 2021. Minor Intron Splicing from Basic Science to Disease.. Int J Mol Sci 22(11) PMID: 34199764
- 8. Xiong F et al.. 2020. SF3b4: A Versatile Player in Eukaryotic Cells.. Front Cell Dev Biol 8:14 PMID: 32083075
